Patents by Inventor Brett D. Williams

Brett D. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EGFR inhibitors
    Patent number: 11718602
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: August 8, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • Inhibitors of activin receptor-like kinase
    Patent number: 11634422
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: April 25, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian Lewis Hodous, Joseph L. Kim, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin
  • EGFR INHIBITORS
    Publication number: 20230056541
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 23, 2023
    Inventors: John Emmerson Campbell, Thomas A. Dineen, Natasja Brooijmans, Jason D. Brubaker, Meredith Suzanne Eno, Joseph L. Kim, Aysegül Özen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Christopher De Savi
  • EGFR INHIBITORS
    Publication number: 20230026209
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: August 8, 2022
    Publication date: January 26, 2023
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5
    Publication number: 20220389009
    Abstract: Disclosed are compounds having structural formula I, and related salts and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases and conditions such as kidney disease, kidney failure, kidney stones, or polycystic kidney disease, using the compounds of formula (I), and related salts and pharmaceutical compositions.
    Type: Application
    Filed: October 1, 2020
    Publication date: December 8, 2022
    Inventors: Goran Malojcic, Matthew H. Daniels, Brett D. Williams, Maolin Yu, Mark W. Ledeboer, Jean-Christophe P. Harmange, Jenna L. Wang
  • XANTHINE CB1 INHIBITORS
    Publication number: 20220380370
    Abstract: Disclosed are compounds having structural formula I, and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases such as diabetic kidney disease, diabetic nephropathy, obesity-related kidney disease, focal segmental glomerular sclerosis, IgA nephropathy, nephrotic syndrome, kidney fibrosis, Prader Willi syndrome, metabolic syndrome, gastrointestinal diseases, non-alcoholic liver disease, alcoholic liver disease, or non-alcoholic fatty liver disease, using the compounds of Formula (I).
    Type: Application
    Filed: September 25, 2020
    Publication date: December 1, 2022
    Inventors: Maolin Yu, Brett D. Williams, Mark W. Ledeboer, Jean-Christophe P. Harmange, Sydney E. Carra